共 50 条
- [1] Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial [J]. LANCET ONCOLOGY, 2013, 14 (03): : 228 - 235
- [2] Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. LANCET ONCOLOGY, 2019, 20 (06): : 806 - 815
- [4] Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2128 - +
- [8] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1664 - 1670
- [10] Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER plus ) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI). [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)